-
Sector Analysis
Cardiac Resynchronisation Therapy (CRT) Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Cardiac Resynchronisation Therapy Market Report Overview The Cardiac Resynchronisation Therapy (CRT) market size was valued at $3.28 billion in 2023. The market is anticipated to grow at a CAGR of more than 5% from 2023 to 2033. CRT device is used to treat heart failure-induced conduction disturbances and ventricular dyssynchrony. When used in combination with stable, optimal medical therapy, CRT is designed to reduce symptoms and improve cardiac function by restoring the mechanical sequence of ventricular activation and contraction. CRT...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Endometrial Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Fallopian Tube Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Peritoneal Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Pancreatic Ductal Adenocarcinoma Drug Details: Durvalumab (MEDI-4736, Imfinzi,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Diffuse Large B-Cell Lymphoma Drug Details: Durvalumab (MEDI-4736,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Pancreatic Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Metastatic Breast Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi,...